AlloVir Inc. (ALVR): Price and Financial Metrics

AlloVir Inc. (ALVR): $5.78

0.13 (+2.30%)

POWR Rating

Component Grades













Add ALVR to Watchlist
Sign Up

Industry: Biotech



in industry

ALVR Stock Price Chart Interactive Chart >

Price chart for ALVR

ALVR Price/Volume Stats

Current price $5.78 52-week high $10.29
Prev. close $5.65 52-week low $3.17
Day low $5.67 Volume 192,328
Day high $5.91 Avg. volume 228,141
50-day MA $6.13 Dividend yield N/A
200-day MA $6.16 Market Cap 538.48M

AlloVir Inc. (ALVR) Company Bio

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.

ALVR Latest News Stream

Event/Time News Detail
Loading, please wait...

ALVR Latest Social Stream

Loading social stream, please wait...

View Full ALVR Social Stream

Latest ALVR News From Around the Web

Below are the latest news stories about ALLOVIR INC that investors may wish to consider to help them evaluate ALVR as an investment opportunity.

AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know

AlloVir, Inc. (ALVR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | January 25, 2023

How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8%

The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 355.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | January 25, 2023

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year.

Yahoo | January 25, 2023

AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

WALTHAM, Mass., January 09, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced the company’s 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapies, including its lead investigational therapy posoleucel. These updates will be the focus of a corporate presentation by Chief Executive Officer Diana Brainard, M.D., at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January

Yahoo | January 9, 2023

AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., January 03, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST.

Yahoo | January 3, 2023

Read More 'ALVR' Stories Here

ALVR Price Returns

1-mo 12.67%
3-mo -17.78%
6-mo -11.35%
1-year -29.17%
3-year N/A
5-year N/A
YTD 12.67%
2022 -60.36%
2021 -66.34%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6491 seconds.